Navigation Links
Optimizing brachytherapy dose on the same day as the implant can control prostate cancer
Date:6/23/2010

This release is available in Spanish.

Ensuring the optimum radiation dose on the same day as the brachytherapy implant in prostate cancer treatment manages to control the illness in about 95% of the cases. This is the result of research undertaken at the University Hospital of Navarre and published in the latest issue of Brachytherapy, journal of the American Society of Brachytherapy.

As is known, brachytherapy is a radiotherapy treatment involving the insertion of radioactive sources within or near the tumour.

Between 2000 and 2006 the research team analysed the cases of 220 patients suffering from low-risk prostate cancer and who had been treated with iodine-125 brachytherapy seed. The researchers aimed to elucidate the parameters that influence curing amongst these patients. In the case of prostate cancer a long period of observation is required in order to obtain results, "because it is an illness in which relapse problems may occur after 5 years subsequent to the treatment", pointed out Doctor Rafael Martnez-Monge, Director of the Department of the Radiotherapy Oncology Clinic.

Twenty percentage points difference in risk of relapse

Thus the research demonstrated that the radiation dose given during brachytherapy influences patient survival. They found a reliable parameter. They observed that on the day of the brachytherapy implant, those patients with a projected dose less than 147 Gy (gray Gy - is the unit of radiation dose) showed a greater risk of relapse than those with 147 Gy or more. In concrete, they achieved control of the illness in 94.4% of those patients with an optimum implant level, compared to 75.5% amongst those who had a dose less than 147 Gy. This represents almost twenty percentage points difference and it should be remembered that an optimum implant means cure in 95% of the cases.

Moreover, another novel aspect of the research was the study on calculating the radiation dose on the same day of the implant. The international recommendation is that this calculation be carried out 30 days after, because the insertion of the radioactive seeds causes inflammation of the prostate and thus may distort the calculation. In most cases this inflammation disappears after a month. "Nevertheless, at the University Hospital of Navarre, we wish to know from the very day of the implant if the dose is suitable; otherwise, we can make an on-the-spot adjustment, both to ensure the efficacy of the treatment as well as to avoid any subsequent displacement to the patient", explained Doctor Martnez-Monge.


'/>"/>

Contact: Oihane Lakar
o.lakar@elhuyar.com
34-943-363-040
Elhuyar Fundazioa
Source:Eurekalert

Related medicine news :

1. New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer
2. Optimizing Corporate Culture is Critical to the Success of Wellness Programs
3. 4Rs Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance
4. Demand For Mobile Prostate Cancer Brachytherapy Vendor Programs Continues Into 2010
5. Children with cochlear implants have quality of life equal to normal hearing peers
6. Dr. Jay Calvert MD Announces Details on New Patent-Protected Investigational Breast Implants
7. Bone Loss May Accompany Dental Implants
8. Complications common, often linked to trauma in children receiving cochlear implants
9. Voice Control Needs Time to Develop After Cochlear Implant
10. Platelet-rich Plasma Enhances Bone and Tissue Growth for Dental Implants
11. Insightra Medical Launches the Freedom(TM) Ventral Hernia Repair, an Innovative New Way to Deploy Sublay Implants for Ventral Hernias Without Suturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... , ... Levels of a protein in the blood associated with heart disease ... the journal Radiology. , Heart disease and brain disease exact a major burden on ... population. Damage to both organs often occurs at a subclinical stage, or before signs ...
(Date:12/7/2016)... Camarillo, CA (PRWEB) , ... December 07, 2016 ... ... manufacturing high performance connectors, is now promoting to the US market its advanced ... SPRINGTAC®, ODU LAMTAC® and ODU TURNTAC®. These advanced technologies are ideal for ...
(Date:12/7/2016)... ... December 07, 2016 , ... Augustine Insurance Agency, a ... and business owners in the greater Dallas metropolitan area, is announcing a charity ... Foundation. , Established in 2009 by active police professionals in the Dallas region, ...
(Date:12/7/2016)... Queens, NY (PRWEB) , ... December 07, 2016 , ... ... to business owners and families throughout the Five Boroughs, is launching a charity drive ... League works to continue the traditions and spirit of marines and Navy FMF Corpsmen. ...
(Date:12/7/2016)... Honolulu, HI (PRWEB) , ... December 07, 2016 ... ... Dermatology is proud to announce that its fully redesigned website, which launched October ... well as a sleek responsive design and easy-to-navigate layout. Visitors and patients can ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... , Dec. 7, 2016   TraceLink ... Network for connecting the Life Sciences supply chain ... marketplace, today announced that Tjoapack has selected TraceLink,s ... manufacturing customers comply with the rapidly approaching serialization ... Act (DSCSA) in 2017 and the EU Falsified ...
(Date:12/7/2016)... 7, 2016 According to a new market research ... Product Type (Integrated, Standalone), Model (Knowledge-Based), Type (Therapeutic, Diagnostic), User Interactivity (Active, ... is expected to reach USD 1,519.2 Million by 2021 from USD 856.3 ... Continue Reading ... ...
(Date:12/7/2016)... NEW YORK , December 7, 2016 ... Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ), Anthera Pharmaceuticals ... DNAI ), and AveXis Inc. (NASDAQ: ... Biotechnology Sector Index fell roughly 37% to reach a level ... While it is down by approximately 14% for the year, ...
Breaking Medicine Technology: